Global and United States Kidney Cancer Drugs Market Insights, Forecast to 2026

Publisher Name :
Date: 23-Oct-2020
No. of pages: 177
Inquire Before Buying

Kidney Cancer Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Kidney Cancer Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Kidney Cancer Drugs market is segmented into

- Angiogenesis Inhibitors

- mTOR Inhibitors

- Monoclonal Antibodies

- Cytokine Immunotherapy (IL-2)

Segment by Application, the Kidney Cancer Drugs market is segmented into

- Renal cell carcinoma (RCC)

- Transitional cell carcinoma (TCC)

Regional and Country-level Analysis

The Kidney Cancer Drugs market is analysed and market size information is provided by regions (countries).

The key regions covered in the Kidney Cancer Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Kidney Cancer Drugs Market Share Analysis

Kidney Cancer Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Kidney Cancer Drugs business, the date to enter into the Kidney Cancer Drugs market, Kidney Cancer Drugs product introduction, recent developments, etc.

The major vendors covered:

- Bayer

- Roche

- GlaxoSmithKline

- Novartis

- Pfizer

- Abbott Laboratories

- Active Biotech

- Amgen

- Argos Therapeutics

- ArQule

- AVEO Pharmaceuticals

- Bionomics

- Bristol-Myers Squibb

- Cerulean Pharma

- Exelixis

- Genentech

- immatics biotechnologies

- Immunicum

- Ono Pharmaceutical

- Onyx Therapeutics

- Oxford BioMedica

- Prometheus Laboratories

- Seattle Genetics

- Taiwan Liposome

- Tracon Pharmaceuticals

- Wilex

Global and United States Kidney Cancer Drugs Market Insights, Forecast to 2026

Table of Contents
1 Study Coverage
1.1 Kidney Cancer Drugs Product Introduction
1.2 Market Segments
1.3 Key Kidney Cancer Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Kidney Cancer Drugs Market Size Growth Rate by Type
1.4.2 Angiogenesis Inhibitors
1.4.3 mTOR Inhibitors
1.4.4 Monoclonal Antibodies
1.4.5 Cytokine Immunotherapy (IL-2)
1.5 Market by Application
1.5.1 Global Kidney Cancer Drugs Market Size Growth Rate by Application
1.5.2 Renal cell carcinoma (RCC)
1.5.3 Transitional cell carcinoma (TCC)
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Kidney Cancer Drugs Market Size, Estimates and Forecasts
2.1.1 Global Kidney Cancer Drugs Revenue 2015-2026
2.1.2 Global Kidney Cancer Drugs Sales 2015-2026
2.2 Global Kidney Cancer Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.3 Kidney Cancer Drugs Historical Market Size by Region (2015-2020)
2.3.1 Global Kidney Cancer Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.3.2 Global Kidney Cancer Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
2.4 Kidney Cancer Drugs Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Kidney Cancer Drugs Sales Forecast by Region (2021-2026)
2.4.2 Global Kidney Cancer Drugs Revenue Forecast by Region (2021-2026)
3 Global Kidney Cancer Drugs Competitor Landscape by Players
3.1 Global Top Kidney Cancer Drugs Sales by Manufacturers
3.1.1 Global Kidney Cancer Drugs Sales by Manufacturers (2015-2020)
3.1.2 Global Kidney Cancer Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Global Kidney Cancer Drugs Manufacturers by Revenue
3.2.1 Global Kidney Cancer Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Global Kidney Cancer Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Kidney Cancer Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Kidney Cancer Drugs Revenue in 2019
3.2.5 Global Kidney Cancer Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Kidney Cancer Drugs Price by Manufacturers
3.4 Global Kidney Cancer Drugs Manufacturing Base Distribution, Product Types
3.4.1 Kidney Cancer Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Kidney Cancer Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Kidney Cancer Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Kidney Cancer Drugs Market Size by Type (2015-2020)
4.1.1 Global Kidney Cancer Drugs Sales by Type (2015-2020)
4.1.2 Global Kidney Cancer Drugs Revenue by Type (2015-2020)
4.1.3 Kidney Cancer Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Kidney Cancer Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Kidney Cancer Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Kidney Cancer Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Kidney Cancer Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Kidney Cancer Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Kidney Cancer Drugs Market Size by Application (2015-2020)
5.1.1 Global Kidney Cancer Drugs Sales by Application (2015-2020)
5.1.2 Global Kidney Cancer Drugs Revenue by Application (2015-2020)
5.1.3 Kidney Cancer Drugs Price by Application (2015-2020)
5.2 Kidney Cancer Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Kidney Cancer Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Kidney Cancer Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Kidney Cancer Drugs Price Forecast by Application (2021-2026)
6 United States by Players, Type and Application
6.1 United States Kidney Cancer Drugs Market Size YoY Growth 2015-2026
6.1.1 United States Kidney Cancer Drugs Sales YoY Growth 2015-2026
6.1.2 United States Kidney Cancer Drugs Revenue YoY Growth 2015-2026
6.1.3 United States Kidney Cancer Drugs Market Share in Global Market 2015-2026
6.2 United States Kidney Cancer Drugs Market Size by Players (International and Local Players)
6.2.1 United States Top Kidney Cancer Drugs Players by Sales (2015-2020)
6.2.2 United States Top Kidney Cancer Drugs Players by Revenue (2015-2020)
6.3 United States Kidney Cancer Drugs Historic Market Review by Type (2015-2020)
6.3.1 United States Kidney Cancer Drugs Sales Market Share by Type (2015-2020)
6.3.2 United States Kidney Cancer Drugs Revenue Market Share by Type (2015-2020)
6.3.3 United States Kidney Cancer Drugs Price by Type (2015-2020)
6.4 United States Kidney Cancer Drugs Market Estimates and Forecasts by Type (2021-2026)
6.4.1 United States Kidney Cancer Drugs Sales Forecast by Type (2021-2026)
6.4.2 United States Kidney Cancer Drugs Revenue Forecast by Type (2021-2026)
6.4.3 United States Kidney Cancer Drugs Price Forecast by Type (2021-2026)
6.5 United States Kidney Cancer Drugs Historic Market Review by Application (2015-2020)
6.5.1 United States Kidney Cancer Drugs Sales Market Share by Application (2015-2020)
6.5.2 United States Kidney Cancer Drugs Revenue Market Share by Application (2015-2020)
6.5.3 United States Kidney Cancer Drugs Price by Application (2015-2020)
6.6 United States Kidney Cancer Drugs Market Estimates and Forecasts by Application (2021-2026)
6.6.1 United States Kidney Cancer Drugs Sales Forecast by Application (2021-2026)
6.6.2 United States Kidney Cancer Drugs Revenue Forecast by Application (2021-2026)
6.6.3 United States Kidney Cancer Drugs Price Forecast by Application (2021-2026)
7 North America
7.1 North America Kidney Cancer Drugs Market Size YoY Growth 2015-2026
7.2 North America Kidney Cancer Drugs Market Facts & Figures by Country
7.2.1 North America Kidney Cancer Drugs Sales by Country (2015-2020)
7.2.2 North America Kidney Cancer Drugs Revenue by Country (2015-2020)
7.2.3 U.S.
7.2.4 Canada
8 Europe
8.1 Europe Kidney Cancer Drugs Market Size YoY Growth 2015-2026
8.2 Europe Kidney Cancer Drugs Market Facts & Figures by Country
8.2.1 Europe Kidney Cancer Drugs Sales by Country
8.2.2 Europe Kidney Cancer Drugs Revenue by Country
8.2.3 Germany
8.2.4 France
8.2.5 U.K.
8.2.6 Italy
8.2.7 Russia
9 Asia Pacific
9.1 Asia Pacific Kidney Cancer Drugs Market Size YoY Growth 2015-2026
9.2 Asia Pacific Kidney Cancer Drugs Market Facts & Figures by Country
9.2.1 Asia Pacific Kidney Cancer Drugs Sales by Region (2015-2020)
9.2.2 Asia Pacific Kidney Cancer Drugs Revenue by Region
9.2.3 China
9.2.4 Japan
9.2.5 South Korea
9.2.6 India
9.2.7 Australia
9.2.8 Taiwan
9.2.9 Indonesia
9.2.10 Thailand
9.2.11 Malaysia
9.2.12 Philippines
9.2.13 Vietnam
10 Latin America
10.1 Latin America Kidney Cancer Drugs Market Size YoY Growth 2015-2026
10.2 Latin America Kidney Cancer Drugs Market Facts & Figures by Country
10.2.1 Latin America Kidney Cancer Drugs Sales by Country
10.2.2 Latin America Kidney Cancer Drugs Revenue by Country
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Kidney Cancer Drugs Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Kidney Cancer Drugs Market Facts & Figures by Country
11.2.1 Middle East and Africa Kidney Cancer Drugs Sales by Country
11.2.2 Middle East and Africa Kidney Cancer Drugs Revenue by Country
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Bayer
12.1.1 Bayer Corporation Information
12.1.2 Bayer Description and Business Overview
12.1.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Bayer Kidney Cancer Drugs Products Offered
12.1.5 Bayer Recent Development
12.2 Roche
12.2.1 Roche Corporation Information
12.2.2 Roche Description and Business Overview
12.2.3 Roche Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Roche Kidney Cancer Drugs Products Offered
12.2.5 Roche Recent Development
12.3 GlaxoSmithKline
12.3.1 GlaxoSmithKline Corporation Information
12.3.2 GlaxoSmithKline Description and Business Overview
12.3.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
12.3.4 GlaxoSmithKline Kidney Cancer Drugs Products Offered
12.3.5 GlaxoSmithKline Recent Development
12.4 Novartis
12.4.1 Novartis Corporation Information
12.4.2 Novartis Description and Business Overview
12.4.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Novartis Kidney Cancer Drugs Products Offered
12.4.5 Novartis Recent Development
12.5 Pfizer
12.5.1 Pfizer Corporation Information
12.5.2 Pfizer Description and Business Overview
12.5.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Pfizer Kidney Cancer Drugs Products Offered
12.5.5 Pfizer Recent Development
12.6 Abbott Laboratories
12.6.1 Abbott Laboratories Corporation Information
12.6.2 Abbott Laboratories Description and Business Overview
12.6.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Abbott Laboratories Kidney Cancer Drugs Products Offered
12.6.5 Abbott Laboratories Recent Development
12.7 Active Biotech
12.7.1 Active Biotech Corporation Information
12.7.2 Active Biotech Description and Business Overview
12.7.3 Active Biotech Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Active Biotech Kidney Cancer Drugs Products Offered
12.7.5 Active Biotech Recent Development
12.8 Amgen
12.8.1 Amgen Corporation Information
12.8.2 Amgen Description and Business Overview
12.8.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Amgen Kidney Cancer Drugs Products Offered
12.8.5 Amgen Recent Development
12.9 Argos Therapeutics
12.9.1 Argos Therapeutics Corporation Information
12.9.2 Argos Therapeutics Description and Business Overview
12.9.3 Argos Therapeutics Sales, Revenue and Gross Margin (2015-2020)
12.9.4 Argos Therapeutics Kidney Cancer Drugs Products Offered
12.9.5 Argos Therapeutics Recent Development
12.10 ArQule
12.10.1 ArQule Corporation Information
12.10.2 ArQule Description and Business Overview
12.10.3 ArQule Sales, Revenue and Gross Margin (2015-2020)
12.10.4 ArQule Kidney Cancer Drugs Products Offered
12.10.5 ArQule Recent Development
12.11 Bayer
12.11.1 Bayer Corporation Information
12.11.2 Bayer Description and Business Overview
12.11.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Bayer Kidney Cancer Drugs Products Offered
12.11.5 Bayer Recent Development
12.12 Bionomics
12.12.1 Bionomics Corporation Information
12.12.2 Bionomics Description and Business Overview
12.12.3 Bionomics Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Bionomics Products Offered
12.12.5 Bionomics Recent Development
12.13 Bristol-Myers Squibb
12.13.1 Bristol-Myers Squibb Corporation Information
12.13.2 Bristol-Myers Squibb Description and Business Overview
12.13.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Bristol-Myers Squibb Products Offered
12.13.5 Bristol-Myers Squibb Recent Development
12.14 Cerulean Pharma
12.14.1 Cerulean Pharma Corporation Information
12.14.2 Cerulean Pharma Description and Business Overview
12.14.3 Cerulean Pharma Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Cerulean Pharma Products Offered
12.14.5 Cerulean Pharma Recent Development
12.15 Exelixis
12.15.1 Exelixis Corporation Information
12.15.2 Exelixis Description and Business Overview
12.15.3 Exelixis Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Exelixis Products Offered
12.15.5 Exelixis Recent Development
12.16 Genentech
12.16.1 Genentech Corporation Information
12.16.2 Genentech Description and Business Overview
12.16.3 Genentech Sales, Revenue and Gross Margin (2015-2020)
12.16.4 Genentech Products Offered
12.16.5 Genentech Recent Development
12.17 immatics biotechnologies
12.17.1 immatics biotechnologies Corporation Information
12.17.2 immatics biotechnologies Description and Business Overview
12.17.3 immatics biotechnologies Sales, Revenue and Gross Margin (2015-2020)
12.17.4 immatics biotechnologies Products Offered
12.17.5 immatics biotechnologies Recent Development
12.18 Immunicum
12.18.1 Immunicum Corporation Information
12.18.2 Immunicum Description and Business Overview
12.18.3 Immunicum Sales, Revenue and Gross Margin (2015-2020)
12.18.4 Immunicum Products Offered
12.18.5 Immunicum Recent Development
12.19 Ono Pharmaceutical
12.19.1 Ono Pharmaceutical Corporation Information
12.19.2 Ono Pharmaceutical Description and Business Overview
12.19.3 Ono Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
12.19.4 Ono Pharmaceutical Products Offered
12.19.5 Ono Pharmaceutical Recent Development
12.20 Onyx Therapeutics
12.20.1 Onyx Therapeutics Corporation Information
12.20.2 Onyx Therapeutics Description and Business Overview
12.20.3 Onyx Therapeutics Sales, Revenue and Gross Margin (2015-2020)
12.20.4 Onyx Therapeutics Products Offered
12.20.5 Onyx Therapeutics Recent Development
12.21 Oxford BioMedica
12.21.1 Oxford BioMedica Corporation Information
12.21.2 Oxford BioMedica Description and Business Overview
12.21.3 Oxford BioMedica Sales, Revenue and Gross Margin (2015-2020)
12.21.4 Oxford BioMedica Products Offered
12.21.5 Oxford BioMedica Recent Development
12.22 Prometheus Laboratories
12.22.1 Prometheus Laboratories Corporation Information
12.22.2 Prometheus Laboratories Description and Business Overview
12.22.3 Prometheus Laboratories Sales, Revenue and Gross Margin (2015-2020)
12.22.4 Prometheus Laboratories Products Offered
12.22.5 Prometheus Laboratories Recent Development
12.23 Seattle Genetics
12.23.1 Seattle Genetics Corporation Information
12.23.2 Seattle Genetics Description and Business Overview
12.23.3 Seattle Genetics Sales, Revenue and Gross Margin (2015-2020)
12.23.4 Seattle Genetics Products Offered
12.23.5 Seattle Genetics Recent Development
12.24 Taiwan Liposome
12.24.1 Taiwan Liposome Corporation Information
12.24.2 Taiwan Liposome Description and Business Overview
12.24.3 Taiwan Liposome Sales, Revenue and Gross Margin (2015-2020)
12.24.4 Taiwan Liposome Products Offered
12.24.5 Taiwan Liposome Recent Development
12.25 Tracon Pharmaceuticals
12.25.1 Tracon Pharmaceuticals Corporation Information
12.25.2 Tracon Pharmaceuticals Description and Business Overview
12.25.3 Tracon Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
12.25.4 Tracon Pharmaceuticals Products Offered
12.25.5 Tracon Pharmaceuticals Recent Development
12.26 Wilex
12.26.1 Wilex Corporation Information
12.26.2 Wilex Description and Business Overview
12.26.3 Wilex Sales, Revenue and Gross Margin (2015-2020)
12.26.4 Wilex Products Offered
12.26.5 Wilex Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Kidney Cancer Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Kidney Cancer Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Kidney Cancer Drugs Market Segments
Table 2. Ranking of Global Top Kidney Cancer Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Kidney Cancer Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Angiogenesis Inhibitors
Table 5. Major Manufacturers of mTOR Inhibitors
Table 6. Major Manufacturers of Monoclonal Antibodies
Table 7. Major Manufacturers of Cytokine Immunotherapy (IL-2)
Table 8. Global Kidney Cancer Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 9. Global Kidney Cancer Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 10. Global Kidney Cancer Drugs Sales by Regions 2015-2020 (K Units)
Table 11. Global Kidney Cancer Drugs Sales Market Share by Regions (2015-2020)
Table 12. Global Kidney Cancer Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Kidney Cancer Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 14. Global Kidney Cancer Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 15. Global Kidney Cancer Drugs Sales Share by Manufacturers (2015-2020)
Table 16. Global Kidney Cancer Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Kidney Cancer Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Kidney Cancer Drugs as of 2019)
Table 18. Kidney Cancer Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Kidney Cancer Drugs Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Kidney Cancer Drugs Price (2015-2020) (USD/Unit)
Table 21. Kidney Cancer Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Kidney Cancer Drugs Product Type
Table 23. Date of International Manufacturers Enter into Kidney Cancer Drugs Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Kidney Cancer Drugs Sales by Type (2015-2020) (K Units)
Table 26. Global Kidney Cancer Drugs Sales Share by Type (2015-2020)
Table 27. Global Kidney Cancer Drugs Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Kidney Cancer Drugs Revenue Share by Type (2015-2020)
Table 29. Kidney Cancer Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 30. Global Kidney Cancer Drugs Sales Share by Type (2021-2026)
Table 31. Global Kidney Cancer Drugs Sales by Application (2015-2020) (K Units)
Table 32. Global Kidney Cancer Drugs Sales Share by Application (2015-2020)
Table 33. Global Kidney Cancer Drugs Sales Share by Application (2021-2026)
Table 34. Global Kidney Cancer Drugs Sales Market Share Forecast by Application (2021-2026)
Table 35. Global Kidney Cancer Drugs Revenue by Application (2015-2020) (US$ Million)
Table 36. Global Kidney Cancer Drugs Revenue Market Share Forecast by Application (2021-2026)
Table 37. United States Kidney Cancer Drugs Sales (K Units) of Key Companies (2015-2020)
Table 38. United States Kidney Cancer Drugs Sales Share by Company (2015-2020)
Table 39. United States Kidney Cancer Drugs Revenue (US$ Million) by Company (2015-2020)
Table 40. United States Kidney Cancer Drugs Sales (K Units) by Type (2015-2020)
Table 41. United States Kidney Cancer Drugs Sales Share by Type (2015-2020)
Table 42. United States Kidney Cancer Drugs Revenue (US$ Million) Market Share by Type (2015-2020)
Table 43. United States Kidney Cancer Drugs Price (K Units) by Type (2015-2020)
Table 44. United States Kidney Cancer Drugs Sales (K Units) by Type (2021-2026)
Table 45. United States Kidney Cancer Drugs Sales Share by Type (2021-2026)
Table 46. United States Kidney Cancer Drugs Revenue (US$ Million) Market Share by Type (2021-2026)
Table 47. United States Kidney Cancer Drugs Revenue Share by Type (2021-2026)
Table 48. United States Kidney Cancer Drugs Price (K Units) by Type (2021-2026)
Table 49. United States Kidney Cancer Drugs Sales (K Units) by Application (2015-2020)
Table 50. United States Kidney Cancer Drugs Sales Share by Application (2015-2020)
Table 51. United States Kidney Cancer Drugs Revenue (US$ Million) Market Share by Application (2015-2020)
Table 52. United States Kidney Cancer Drugs Sales (K Units) by Application (2021-2026)
Table 53. United States Kidney Cancer Drugs Sales Share by Application (2021-2026)
Table 54. United States Kidney Cancer Drugs Revenue (US$ Million) Market Share by Application (2021-2026)
Table 55. United States Kidney Cancer Drugs Revenue Share by Application (2021-2026)
Table 56. North America Kidney Cancer Drugs Sales by Country (2015-2020) (K Units)
Table 57. North America Kidney Cancer Drugs Sales Market Share by Country (2015-2020)
Table 58. North America Kidney Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 59. North America Kidney Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 60. Europe Kidney Cancer Drugs Sales by Country (2015-2020) (K Units)
Table 61. Europe Kidney Cancer Drugs Sales Market Share by Country (2015-2020)
Table 62. Europe Kidney Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 63. Europe Kidney Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 64. Asia Pacific Kidney Cancer Drugs Sales by Region (2015-2020) (K Units)
Table 65. Asia Pacific Kidney Cancer Drugs Sales Market Share by Region (2015-2020)
Table 66. Asia Pacific Kidney Cancer Drugs Revenue by Region (2015-2020) (US$ Million)
Table 67. Asia Pacific Kidney Cancer Drugs Revenue Market Share by Region (2015-2020)
Table 68. Latin America Kidney Cancer Drugs Sales by Country (2015-2020) (K Units)
Table 69. Latin America Kidney Cancer Drugs Sales Market Share by Country (2015-2020)
Table 70. Latin Americaa Kidney Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 71. Latin America Kidney Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 72. Middle East and Africa Kidney Cancer Drugs Sales by Country (2015-2020) (K Units)
Table 73. Middle East and Africa Kidney Cancer Drugs Sales Market Share by Country (2015-2020)
Table 74. Middle East and Africa Kidney Cancer Drugs Revenue by Country (2015-2020) (US$ Million)
Table 75. Middle East and Africa Kidney Cancer Drugs Revenue Market Share by Country (2015-2020)
Table 76. Bayer Corporation Information
Table 77. Bayer Description and Business Overview
Table 78. Bayer Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 79. Bayer Kidney Cancer Drugs Product
Table 80. Bayer Recent Development
Table 81. Roche Corporation Information
Table 82. Roche Description and Business Overview
Table 83. Roche Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 84. Roche Product
Table 85. Roche Recent Development
Table 86. GlaxoSmithKline Corporation Information
Table 87. GlaxoSmithKline Description and Business Overview
Table 88. GlaxoSmithKline Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 89. GlaxoSmithKline Product
Table 90. GlaxoSmithKline Recent Development
Table 91. Novartis Corporation Information
Table 92. Novartis Description and Business Overview
Table 93. Novartis Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 94. Novartis Product
Table 95. Novartis Recent Development
Table 96. Pfizer Corporation Information
Table 97. Pfizer Description and Business Overview
Table 98. Pfizer Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 99. Pfizer Product
Table 100. Pfizer Recent Development
Table 101. Abbott Laboratories Corporation Information
Table 102. Abbott Laboratories Description and Business Overview
Table 103. Abbott Laboratories Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 104. Abbott Laboratories Product
Table 105. Abbott Laboratories Recent Development
Table 106. Active Biotech Corporation Information
Table 107. Active Biotech Description and Business Overview
Table 108. Active Biotech Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 109. Active Biotech Product
Table 110. Active Biotech Recent Development
Table 111. Amgen Corporation Information
Table 112. Amgen Description and Business Overview
Table 113. Amgen Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 114. Amgen Product
Table 115. Amgen Recent Development
Table 116. Argos Therapeutics Corporation Information
Table 117. Argos Therapeutics Description and Business Overview
Table 118. Argos Therapeutics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 119. Argos Therapeutics Product
Table 120. Argos Therapeutics Recent Development
Table 121. ArQule Corporation Information
Table 122. ArQule Description and Business Overview
Table 123. ArQule Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 124. ArQule Product
Table 125. ArQule Recent Development
Table 126. AVEO Pharmaceuticals Corporation Information
Table 127. AVEO Pharmaceuticals Description and Business Overview
Table 128. AVEO Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 129. AVEO Pharmaceuticals Product
Table 130. AVEO Pharmaceuticals Recent Development
Table 131. Bionomics Corporation Information
Table 132. Bionomics Description and Business Overview
Table 133. Bionomics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 134. Bionomics Product
Table 135. Bionomics Recent Development
Table 136. Bristol-Myers Squibb Corporation Information
Table 137. Bristol-Myers Squibb Description and Business Overview
Table 138. Bristol-Myers Squibb Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 139. Bristol-Myers Squibb Product
Table 140. Bristol-Myers Squibb Recent Development
Table 141. Cerulean Pharma Corporation Information
Table 142. Cerulean Pharma Description and Business Overview
Table 143. Cerulean Pharma Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 144. Cerulean Pharma Product
Table 145. Cerulean Pharma Recent Development
Table 146. Exelixis Corporation Information
Table 147. Exelixis Description and Business Overview
Table 148. Exelixis Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 149. Exelixis Product
Table 150. Exelixis Recent Development
Table 151. Genentech Corporation Information
Table 152. Genentech Description and Business Overview
Table 153. Genentech Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 154. Genentech Product
Table 155. Genentech Recent Development
Table 156. immatics biotechnologies Corporation Information
Table 157. immatics biotechnologies Description and Business Overview
Table 158. immatics biotechnologies Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 159. immatics biotechnologies Product
Table 160. immatics biotechnologies Recent Development
Table 161. Immunicum Corporation Information
Table 162. Immunicum Description and Business Overview
Table 163. Immunicum Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 164. Immunicum Product
Table 165. Immunicum Recent Development
Table 166. Ono Pharmaceutical Corporation Information
Table 167. Ono Pharmaceutical Description and Business Overview
Table 168. Ono Pharmaceutical Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 169. Ono Pharmaceutical Product
Table 170. Ono Pharmaceutical Recent Development
Table 171. Onyx Therapeutics Corporation Information
Table 172. Onyx Therapeutics Description and Business Overview
Table 173. Onyx Therapeutics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 174. Onyx Therapeutics Product
Table 175. Onyx Therapeutics Recent Development
Table 176. Oxford BioMedica Corporation Information
Table 177. Oxford BioMedica Description and Business Overview
Table 178. Oxford BioMedica Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 179. Oxford BioMedica Product
Table 180. Oxford BioMedica Recent Development
Table 181. Prometheus Laboratories Corporation Information
Table 182. Prometheus Laboratories Description and Business Overview
Table 183. Prometheus Laboratories Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 184. Prometheus Laboratories Product
Table 185. Prometheus Laboratories Recent Development
Table 186. Seattle Genetics Corporation Information
Table 187. Seattle Genetics Description and Business Overview
Table 188. Seattle Genetics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 189. Seattle Genetics Product
Table 190. Seattle Genetics Recent Development
Table 191. Taiwan Liposome Corporation Information
Table 192. Taiwan Liposome Description and Business Overview
Table 193. Taiwan Liposome Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 194. Taiwan Liposome Product
Table 195. Taiwan Liposome Recent Development
Table 196. Tracon Pharmaceuticals Corporation Information
Table 197. Tracon Pharmaceuticals Description and Business Overview
Table 198. Tracon Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 199. Tracon Pharmaceuticals Product
Table 200. Tracon Pharmaceuticals Recent Development
Table 201. Wilex Corporation Information
Table 202. Wilex Description and Business Overview
Table 203. Wilex Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 204. Wilex Product
Table 205. Wilex Recent Development
Table 206. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 207. Key Challenges
Table 208. Market Risks
Table 209. Main Points Interviewed from Key Kidney Cancer Drugs Players
Table 210. Kidney Cancer Drugs Customers List
Table 211. Kidney Cancer Drugs Distributors List
Table 212. Research Programs/Design for This Report
Table 213. Key Data Information from Secondary Sources
Table 214. Key Data Information from Primary Sources
List of Figures
Figure 1. Kidney Cancer Drugs Product Picture
Figure 2. Global Kidney Cancer Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Angiogenesis Inhibitors Product Picture
Figure 4. mTOR Inhibitors Product Picture
Figure 5. Monoclonal Antibodies Product Picture
Figure 6. Cytokine Immunotherapy (IL-2) Product Picture
Figure 7. Global Kidney Cancer Drugs Sales Market Share by Application in 2020 & 2026
Figure 8. Renal cell carcinoma (RCC)
Figure 9. Transitional cell carcinoma (TCC)
Figure 10. Kidney Cancer Drugs Report Years Considered
Figure 11. Global Kidney Cancer Drugs Market Size 2015-2026 (US$ Million)
Figure 12. Global Kidney Cancer Drugs Sales 2015-2026 (K Units)
Figure 13. Global Kidney Cancer Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Kidney Cancer Drugs Sales Market Share by Region (2015-2020)
Figure 15. Global Kidney Cancer Drugs Sales Market Share by Region in 2019
Figure 16. Global Kidney Cancer Drugs Revenue Market Share by Region (2015-2020)
Figure 17. Global Kidney Cancer Drugs Revenue Market Share by Region in 2019
Figure 18. Global Kidney Cancer Drugs Sales Share by Manufacture
  • Global Colorectal Cancer Drugs Market Outlook 2021
    Published: 23-Nov-2020        Price: US 2900 Onwards        Pages: 121
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment , the Colorectal Cancer Drugs market is segmented into - Vascular Endothelial Growth Factor (VEGF) Inhibitors - Epidermal Gr......
  • Global and China Multiple Myeloma Drugs Market Insights, Forecast to 2026
    Published: 23-Nov-2020        Price: US 3900 Onwards        Pages: 133
    Multiple Myeloma Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Multiple Myeloma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026. Segment by Type, the Multiple Myeloma Drugs mark......
  • (Post-pandemic Era) - Global Kidney Cancer Drugs Market 2015-2026, With Breakdown Data of Capacity, Sales, Production, Export, Import, Revenue, Price, Cost and Gross Margin
    Published: 20-Nov-2020        Price: US 3620 Onwards        Pages: 116
    Summary World trade was already slowing in 2019 before COVID 19 outbreak, weighed down by trade tensions and slowing economic growth, such as uncertainty generated from Brexit, the U.S.-China trade war, the Japan-South Korea trade war. Trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world, according to the study of WTO.The decline in exports has been mainly due to the ongoing glo......
  • (Post-pandemic Era) - Global Kidney Cancer Drugs Market Assessment, With Major Companies Analysis, Regional Analysis, Breakdown Data by Application/Type
    Published: 20-Nov-2020        Price: US 4860 Onwards        Pages: 99
    Summary This study analysis was given on a worldwide scale, for instance, present and historical Kidney Cancer Drugs growth analysis, Competitive Analysis, and also the growth prospects of the major regions. The report gives an exhaustive investigation of this market at country & regional levels, and provides an analysis of the industry trends in each of the sub-segments, from production, revenue and consumption. A quantitative and qualitative analysis of the main players i......
  • Global Cancer Treatment Drugs Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)
    Published: 19-Nov-2020        Price: US 3400 Onwards        Pages: 128
    The Cancer Treatment Drugs market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Cancer Treatment Drugs market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Cancer Treatment Drugs market. The report focuses on well-known providers in the global Cancer Treatment Drugs industry, market segments, comp......
  • Global Kidney Cancer Drugs Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)
    Published: 19-Nov-2020        Price: US 3400 Onwards        Pages: 106
    The Kidney Cancer Drugs market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Kidney Cancer Drugs market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Kidney Cancer Drugs market. The report focuses on well-known providers in the global Kidney Cancer Drugs industry, market segments, competition, and......
  • Global Hydroxycarbamide Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)
    Published: 19-Nov-2020        Price: US 3400 Onwards        Pages: 118
    The Hydroxycarbamide market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Hydroxycarbamide market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Hydroxycarbamide market. The report focuses on well-known providers in the global Hydroxycarbamide industry, market segments, competition, and the macro e......
  • Mitomycin C Market Status and Trend Analysis 2017-2026 (COVID-19 Version)
    Published: 19-Nov-2020        Price: US 2800 Onwards        Pages: 107
    Summary Further key aspects of the report indicate that: Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology Chapter 2: Global Industry Summary Chapter 3: Market Dynamics Chapter 4: Global Market Segmentation by region, type and End-Use Chapter 5: North America Market Segmentation by region, type and End-Use Chapter 6: Europe Market Segmentation by region, type and End-Use Chapter 7: Asia-Pacific Market Segmen......
  • Global 5-Fluorouracil Market Outlook 2021
    Published: 18-Nov-2020        Price: US 2900 Onwards        Pages: 90
    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type, the 5-Fluorouracil market is segmented into - High Purity - Low Purity Segment by Application ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs